Dr Reddy’s Laboratories moved higher by 3% to Rs 2,473, extending its Thursday’s 3% gain on BSE, after the company clarified that it has no updates regarding the establishment inspection report (EIR) for Duvvada facility. The stock is trading at its highest level since November 21, 2017 on BSE.
On Wednesday, January 3, the stock had dipped 3% on the buzz of issues raised in EIR for Duvvada plant.
"The company has already intimated the stock exchanges on November 21, 2017 regarding the updated status of US Food and Drug Administration (USFDA) audit of our formulations manufacturing facility
On Wednesday, January 3, the stock had dipped 3% on the buzz of issues raised in EIR for Duvvada plant.
"The company has already intimated the stock exchanges on November 21, 2017 regarding the updated status of US Food and Drug Administration (USFDA) audit of our formulations manufacturing facility